Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma

NCT02409524 is registered in ClinicalTrials.gov with Mirror Biologics, Inc. as lead sponsor.

NCT NCT02409524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02409524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
Mirror Biologics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
March 31, 2019
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma